AstraZeneca bolsters heart failure and metabolic disease research
This article was originally published in Scrip
Executive Summary
AstraZeneca and its MedImmune unit have signed a couple of early stage research deals aimed at boosting their cardiovascular and metabolic pipeline efforts – one of its three core therapeutic areas.